Zydus Set To Enter NASH Fray As US Trial Approved
This article was originally published in PharmAsia News
Executive Summary
Indian pharmaceutical company Zydus Cadila says the US Food and Drug Administration has endorsed its plans to conduct a Phase II clinical trial in the US of saroglitazar, its flagship novel drug to treat severe hypertriglyceridemia which can cause serious conditions like non-alcoholic steatohepatitis.